Biomedical subjects
Publications and source records attributed to E Lindgren.
Explore the source record for details and available documents.
N-ethylmaleimide (NEM) has been reported to interact with the GTP-binding Ni-protein; we have examined its effect on adenosine receptor binding in feline cortical membranes and on adenosine-receptor mediated effects on cyclic AMP accumulation in rat hippocampal slices. Treatment of cortical membranes with NEM (100 microM for 5 min) altered the binding of [3H]-phenylisopropyladenosine (PIA) from being almost exclusively to a single class of high affinity sites (KD = 1.65 nM) to binding at two classes of sites (KDH = 2.1 nM, KDL = 102 nM). The total number of binding sites was similar (825-845 fmol mg-1 in control membranes, 944-1428 fmol mg-1 in NEM-treated membranes). In rat hippocampal slices treated with forskolin (0.3 microM) L-PIA produced a biphasic effect on cyclic AMP accumulation: an inhibition at 0.03 to 1 microM and at higher concentrations, a stimulation. Treatment with 50 microM NEM selectively inhibited the inhibitory phase, causing stimulation at lower concentrations of L-PIA. At 50 microM, NEM did not alter basal or forskolin-stimulated cyclic AMP accumulation but at higher concentrations inhibition was observed. It is concluded that NEM can, in certain doses, selectively block adenosine A1-receptor-mediated effects without affecting A2-receptor-mediated actions in the same tissue. It is suggested that this is due to NEM affecting the Ni guanine nucleotide binding protein.
Cyclic AMP accumulation and glycerol release were studied in isolated rat fat cells. Both processes were inhibited by R-site specific adenosine analogues (L-PIA greater than NECA greater than 2-chloro-adenosine greater than D-PIA), but poorly or not at all by the P-site selective analogue SQ 22,536. The effect of a series of xanthine derivatives and of some structurally unrelated phosphodiesterase inhibitors as inhibitors of 2-chloro-adenosine induced inhibition of NA stimulated cyclic AMP accumulation and lipolysis was subsequently examined. The 2-chloroadenosine effect on cyclic AMP accumulation was antagonized by the xanthines with the following order of potency: DPX greater than 8-phenyl-theophylline greater than 8-p-sulpho-phenyl-theophylline greater than verrophylline greater than IBMX greater than theophylline greater than HWA 285 greater than pentoxiphylline greater than caffeine greater than 7-benzyl IBMX greater than theobromine greater than enprofylline greater greater than ZK 62,711. The rank order potency of xanthines against the antilipolytic effect of 2-chloro-adenosine was the same with two notable exceptions: the two potent phosphodiesterase inhibitors 7-benzyl-IBMX and ZK 62,711 were more than 20 times more potent as inhibitors of the antilipolytic effect of 2-chloro-adenosine. The results show that antagonism of adenosine analogue-induced antilipolytic effects is a convenient assay for adenosine antagonistic potency of drugs, except for drugs with a high potency as phosphodiesterase inhibitors. The lipolytic potency of the xanthine derivatives was also studied. The ability of the xanthines to stimulate basal and noradrenaline stimulated lipolysis was generally in agreement with their potency as adenosine antagonists. Adenosine deaminase induced lipolysis was stimulated by potent phosphodiesterase inhibitors.
The effect of three stable adenosine analogues, L-phenylisopropyl-adenosine (L-PIA), 2-chloroadenosine, and adenosine 5'-ethylcarboxamide (NECA), on cyclic AMP accumulation was studied in five different cell lines derived from the nervous system. In N18-neuroblastoma cells, with cholinergic properties, all three analogues caused an increased accumulation of cyclic AMP with the following relative order of potency: NECA greater than 2-chloroadenosine greater than L-PIA. The half maximal effect of NECA was obtained at close to 10(-8) M concentration. In the two other neuroblastoma cell lines, 41A3 with cholinergic and NIE115 with adrenergic properties, the two analogues NECA and PIA had similar effects. In glioma C6 and 138 MG cells NECA was also found to be more potent that PIA in elevating cyclic AMP levels. However, the absolute potency of NECA in these cell lines was almost 100 times lower. Phosphodiesterase (PDE) activity in crude homogenates of the five cell lines showed essentially similar Km and Vmax, with the exception that the three neuroblastoma cell lines showed biphasic, the glial cell lines monophasic Eadie-Hofstee plots. Theophylline was equally potent as an inhibitor of PDE in all cell lines, but the non-xanthine, inhibitor rolipram, was more potent against neuroblastoma than glial cell PDE. These results indicate that all five cell lines have adenosine receptors of the A2-subtype. However, the apparent affinity of the adenosine analogues to these receptors was markedly different between the neuroblastoma and glial cell lines. The absolute potency of adenosine analogues may be a poor criterion to classify adenosine receptors, into A1 and A2 subtypes, especially when intact cells are used.
The administration of a stable adenosine analogue, L-N6-phenylisopropyladenosine (L-PIA, 0.3 mg/kg i. p.), caused a decrease in the accumulation of L-DOPA in the rat hippocampus after blockade of aromatic amino acid decarboxylase by NSD 1015 (150 mg/kg). Conversely, the adenosine receptor antagonist theophylline (15 mg/kg) increased the L-DOPA accumulation. In slices from rat hippocampus L-PIA causes an inhibition of the stimulation-evoked release of [3H]-noradrenaline (NA). The magnitude of this effect was enhanced after 1 week treatment with theophylline (15 mg/kg/day). The number of beta-adrenoceptors in the rat hippocampus, measured by binding of [3H]-dihydroalprenolol was significantly reduced after theophylline treatment, and tended to be higher after L-PIA treatment. The results show that activation of adenosine receptors in vivo causes a decreased synthesis of NA in the rat hippocampus. The reason may be a reduced firing-rate of the NA-neurons. Theophylline, by contrast, enhanced the synthesis, possibly indicating a role for endogenous adenosine in the regulation of NA-turnover. Long-term treatment with these drugs caused adaptive changes in the presynaptic adenosine receptor activity and in the number of beta-adrenoceptors.
Explore the source record for details and available documents.
Several drugs claimed to protect against anoxic damage to the brain and/or to aleviate symptoms of senility were tested for their ability to influence purine overflow from hypothalamic synaptosomes. Theophylline did not influence the total purine release but tended to decrease the nucleoside and increase the nucleotide release. Cyclic nucleotide phosphodiesterase inhibitors were ineffective, whereas drugs that inhibit carrier mediated nucleoside transport inhibited veratridine-induced purine release. Some ergot derivatives, some vinca-analogues and the vasodilator ifenprodil also decreased stimulated purine release, but their effect could not be attributed to adenosine transport inhibition. The results suggest that drugs are reported to aleviate symptoms of anoxic damage or senility may inhibit the release of adenosine and related compounds in the central nervous system. Some possible reasons why a decreased purine release may protect against ischaemic brain damage are discussed.
Electrical field stimulation elicits a calcium-dependent release of 3H-NA from rat hippocampal slices. The release is inhibited by the alpha 2-agonist clonidine and enhanced by the alpha 2-antagonist yohimbine. The stable adenosine analogue N6-L-phenylisopropyl-adenosine (L-PIA) caused a dose-dependent inhibition of 3H-NA overflow. The effect of L-PIA was antagonized by the adenosine receptor antagonist 8-phenyl-theophylline, which caused a slight, but significant increase in overflow per se. The results suggest that there are functionally important presynaptic adenosine receptors on nor-adrenergic nerve terminals in the rat hippocampus.
In the transversely cut rat hippocampus, adenosine caused a dose-dependent increase in the accumulation of [3H]cyclic AMP from [3H]ATP. Adenosine breakdown products were inactive. AMP was somewhat less effective than adenosine, and its effect could be partially, but not completely, abolished by alpha, beta-methylene-ADP and GMP, which inhibited its metabolism by 5'-nucleotidase. The effect of adenosine was unaffected by inhibitors of adenosine deaminase, but enhanced by several inhibitors of adenosine uptake. Some analogues of adenosine, including N6-phenylisopropyladenosine (PIA), 2-chloroadenosine and adenosine 5'-ethylcarboxamide (NECA), were more active than adenosine, whereas others such as 2-deoxyadenosine and 9-(tetrahydro-2-furyl)adenine (SQ 22536) actually inhibited the response. The effect of PIA was highly stereospecific. The action of adenosine was inhibited by several alkylxanthines, the most potent of which was 8-phenyltheophylline. [3H]Cyclohexyladenosine (CHA) bound specifically to cell membranes from the rat hippocampus. The extent of binding was similar to that found in other cortical areas. The relative potency of some adenosine analogues and alkylxanthines to displace labelled CHA was essentially similar to their potency as effectors of the cyclic AMP system. Adenosine contributed to the cyclic AMP-elevating effect of alpha-adrenoceptor-stimulating drugs and several amino acids, but not to that seen with isoprenaline. The cyclic AMP increase seen following depolarization was only partially adenosine-dependent. The present results demonstrate that the rat hippocampus contains adenosine receptors mediating cyclic AMP accumulation and that these receptors have similar characteristics to those mediating pyramidal cell depression. Adenosine-induced cyclic AMP accumulation may be used as a biochemical correlate to electrophysiology and as a convenient parameter to assess the influence of drugs on adenosine mechanisms in the rat hippocampus.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.